ESTI 2026 //

Lung cancer screening is gaining momentum across Europe — with several countries already running national programs and many more preparing for implementation.

From June 4–6, 2026, we will showcase the Veolity portfolio at ESTI 2026 in Salzburg and demonstrate how our Veolity solutions support radiologists, screening centers, and national screening initiatives at every stage of the workflow.
Our Veolity product family offers the right solution for every screening setup:

• Veolity Lung CAD - AI-powered pulmonary nodule detection, quantification, and follow-up analysis — seamlessly integrated into your PACS workflow.
• Veolity LungRead - An optimized reading solution supporting efficient, guideline-compliant reporting from AI-assisted review to structured reports.
• Veolity One - A centralized cloud-based solution covering the complete organizational and clinical screening workflow — connecting referrers, first and second readers, and screening participants.

With over 10 years of international experience in national lung cancer screening programs and other national pilot projects - including in the UK, Canada, Australia, France, Norway, and Finland, MeVis supports the transition from pilot projects to scalable national screening programs.

Meet us at ESTI 2026 in Salzburg at our booth no. 3 — we look forward to discussing the future of lung cancer screening with you.

Venue:
Salzburg Congress
Auerspergstraße 6
5020 Salzburg
Austria